Sol-Gel Technologies (SLGL) vs Whitehawk Therapeutics (WHWK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Sol-Gel Technologies (SLGL) has outperformed Whitehawk Therapeutics (WHWK) over the past year, gaining 50.5% versus a gain of 45.5%. Over five years, SLGL leads with a -28.4% price change compared with -86.4% for WHWK. Whitehawk Therapeutics is the larger company by market cap ($181.2 million vs $180.6 million), about 1.0 times the size, while Sol-Gel Technologies is growing revenue faster (+68.0% vs -72.5%).
Sol-Gel Technologies converts more of its revenue into profit, with a net margin of -31.6% versus -288.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SLGL | WHWK |
|---|---|---|
| Share price | $55.17 | $3.07 |
| Market cap | $180.63M | $181.16M |
| 1-day change | +2.02% | -1.60% |
| YTD return | +30.92% | +26.86% |
| 1-year return | +50.53% | +45.50% |
| 5-year return | -28.44% | -86.36% |
| EPS (TTM) | $-5.22 | $-1.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $19.39M | $7.14M |
| Revenue growth (YoY) | +68.04% | -72.50% |
| Net income (latest FY) | $-6.13M | $-20.60M |
| Gross margin | — | 89.36% |
| Operating margin | -38.88% | -1601.12% |
| Net margin | -31.60% | -288.26% |
| 52-week high | $97.97 | $5.50 |
| 52-week low | $34.47 | $2.10 |
| Distance from 52-week high | -43.69% | -44.13% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +181.86% | +151.14% |
| Average volume | 47.38K | 348.68K |
| Shares outstanding | 3.27M | 59.01M |
| Employees | 28 | 37 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Sol-Gel Technologies is more profitable, keeping -31.6 cents of every revenue dollar as net income versus -288.3 cents for Whitehawk Therapeutics.
- Sol-Gel Technologies grew revenue faster in its latest fiscal year (+68.04% vs -72.50%).
About Sol-Gel Technologies
SLGL stock →Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Whitehawk Therapeutics
WHWK stock →Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
SLGL vs WHWK FAQ
Which is bigger, Sol-Gel Technologies or Whitehawk Therapeutics?
Whitehawk Therapeutics (WHWK) is larger, with a market capitalization of $181.16M compared with $180.63M for Sol-Gel Technologies (SLGL).
Which stock has performed better over the past year, SLGL or WHWK?
SLGL returned +50.53% over the past 12 months, compared with +45.50% for WHWK (price return, excluding dividends). Past performance does not predict future results.
Are Sol-Gel Technologies and Whitehawk Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.